NCT04793217 (ImpACT+) is a NA clinical trial of Improving AIDS Care After Trauma + in HIV, sponsored by Columbia University.

Who is sponsoring NCT04793217?

NCT04793217 is sponsored by Columbia University.

What drugs are being tested in NCT04793217?

Interventions in NCT04793217: Improving AIDS Care After Trauma +, Adapted Problem-Solving Therapy.

What condition does NCT04793217 study?

NCT04793217 studies HIV, Trauma Exposure.

Is NCT04793217 still recruiting?

NCT04793217 is currently active, enrolled. Last updated 8 July 2025.

Last reviewed 2025-07-08 · How we verify

NCT04793217: ImpACT+

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Randomized Trial of ImpACT+, a Coping Intervention for HIV Infected Women With Sexual Trauma in South Africa

Active, enrolled NA Last updated 8 July 2025

What this trial tests

NA trial testing Improving AIDS Care After Trauma + in HIV in 350 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

18 February 2021

Primary endpoint
30 May 2025

30 May 2026

Quick facts

Lead sponsor	Columbia University
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	350
Start date	18 February 2021
Primary completion	30 May 2025
Estimated completion	30 May 2026
Sites	1 location across South Africa

Drugs / interventions tested

Improving AIDS Care After Trauma +
Adapted Problem-Solving Therapy

Conditions studied

HIV — all drugs for HIV →
Trauma Exposure — all drugs for Trauma Exposure →

Sponsor

Columbia University

Who can join

18 and older, female only, with HIV or Trauma Exposure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

ImpACT+ (Improving AIDS Care after Trauma+), is an individual-level coping intervention to address traumatic stress and HIV care engagement among South African women with sexual trauma histories. We propose a full-scale randomized controlled trial to examine the effect of ImpACT+ on clinical outcomes in the period after ART initiation and to understand mental health and behavioral mechanisms through which viral suppression can be achieved. ImpACT+ will target women who are initiating ART in order to take advantage of a window of opportunity in HIV care and maximize care engagement. The aims are to test the effectiveness of ImpACT+ and explore its potential for implementation.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

The importance of assessing and addressing mental health barriers to PrEP use during pregnancy and postpartum in sub-Saharan Africa: state of the science and research priorities.
Stanton AM, O'Cleirigh C, Knight L, Davey DLJ, et al · · 2022 · cited 10× · PMID 36251124 · DOI 10.1002/jia2.26026
ImpACT+, a coping intervention to improve clinical outcomes for women living with HIV and sexual trauma in South Africa: study protocol for a randomized controlled trial.
Sikkema KJ, Rabie S, King A, Watt MH, et al · · 2022 · cited 6× · PMID 35982485 · DOI 10.1186/s13063-022-06655-5
The Factorial Structure, Reliability, and Validity of a Coping Measure Among Women with HIV and Sexual Trauma in Cape Town, South Africa.
Rabie S, Poudyal A, Mirti A, Wilson P, et al · · 2026 · PMID 40983787 · DOI 10.1007/s10461-025-04886-6

Verify or expand the search:

Other recruiting trials for HIV

Currently open trials in the same condition.

NCT06705478 — Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disor · Phase 2 · recruiting
NCT07221214 — GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV · Phase 2 · recruiting
NCT07226128 — The Effects of Cognitive Behavioral Therapy on Insulin Resistance in People With HIV · NA · recruiting
NCT07390474 — Clinical Trial to Evaluate the Safety and Immunogenicity of the V2 Apex-Directed Immunogens DV201P-RNA and DV202B1-RNA i · Phase 1 · recruiting
NCT07390955 — A Study of Safety and Drug Levels of ePGT121v1-LS, PGDM1400LS, and VRC07-523LS in Adult Participants Without HIV-1 · Phase 1 · recruiting

Other Columbia University trials

Trials by the same sponsor.

NCT06558422 — Human Models of Selective Insulin Resistance: Pancreatic Clamp · Phase 1 · not yet recruiting
NCT07264582 — HIV/STI/HCV Testing and Overdose Prevention Among Survivors of Sex Trafficking · NA · not yet recruiting
NCT05992415 — Know Your Pressures NYC · NA · not yet recruiting
NCT05645211 — The AgRP and GH/IGF-1 Axis in Children · not yet recruiting
NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04793217 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Columbia University
Last refreshed: 8 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04793217.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing